The Future of Biotech Marketing is Personality-Driven

·31 min·1 clip

Anis argues BD teams should stop prospecting and focus on closing qualified deals already in the pipeline.

Chris Conner opens with Anis Fahandij-Sadi’s background and the work behind TLDR biotech. Anis explains that the newsletter began as a LinkedIn compilation called the good, the bad and the ugly. He says the idea grew from watching how biotech news could be sorted into useful buckets. The discussion stays focused on why that format clicked. Chris leans into how the newsletter became more than a hobby project. Anis describes it as a journey that started around April or May of 2024. He talks about the early motivation and how it shifted once the project was out in the world. The conversation then shifts to Science to Sales. Anis outlines the business side of helping biotech service and product providers with lead gen strategy and execution. Chris asks how that move into business development happened. Anis says his path began with a chemistry background and a move into life sciences. He does not frame it as a dramatic leap. Instead, he describes a lot of on-the-job learning. He says he had to figure out prospecting, intro calls, and how to move deals forward mostly by himself. That grounded tone carries through the rest of the discussion. Chris asks what advice he would give someone who wants a similar move. Anis points to the importance of knowing why you want to leave the lab. He also encourages people to make themselves visible. LinkedIn comes up as a central tool. He treats it as a place where people can post, connect, and signal that they are open to sales roles. He also stresses that there are more free resources available now than there used to be. The episode keeps circling back to the same basic idea. Technical background matters, but it is not enough on its own. You still have to learn how to talk to people, build trust, and make your work legible. The final stretch stays practical and generous. Anis keeps the focus on how to learn, where to look, and what to do next.

As heard by us

Biotech sales, lead gen, and LinkedIn discipline shape a practical, useful episode.

TLDR biotech follows a path from a LinkedIn news roundup into a newsletter and then a service business, with a side thread about learning biotech sales on the fly.

Read the full review in PlayNext →

Why you'd press play

Want a clearer path from science background to biotech sales?

Read the full recommendation in PlayNext →

Listen to the show on

Apple Podcasts Spotify

Play clips from this episode More from cc: Life Science Podcast